Resumen de Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%

Sana M. Al Khatib, Anne S. Hellkamp, Gregg C. Fonarow, Daniel B. Mark

• Importance Clinical trials of prophylactic implantable cardioverter-defibrillators (ICDs) have included a minority of patients with a left ventricular ejection fraction (LVEF) between 30% and 35%. Because a large number of ICDs in the United States are implanted in such patients, it is important to study survival associated with this therapy.

  Objective To characterize patients with LVEF between 30% and 35% and compare the survival of those with and without ICDs.